Poractant alfa (Curosurf®) — Competitive Intelligence Brief

Poractant alfa (Curosurf®) (Poractant alfa (Curosurf®)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pulmonary surfactant replacement therapy. Area: Respiratory/Neonatology.

marketed Pulmonary surfactant replacement therapy Respiratory/Neonatology Small molecule

Target snapshot

Poractant alfa (Curosurf®) (Poractant alfa (Curosurf®)) — Chiesi Farmaceutici S.p.A.. Poractant alfa is a natural pulmonary surfactant that reduces surface tension in the lungs and restores normal respiratory function in neonates with respiratory distress syndrome.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Poractant alfa (Curosurf®) TARGET	Poractant alfa (Curosurf®)	Chiesi Farmaceutici S.p.A.	marketed	Pulmonary surfactant replacement therapy
Bolus surfactant	Bolus surfactant	Zekai Tahir Burak Women's Health Research and Education Hospital	marketed	Pulmonary surfactant replacement therapy
Surfactant nebulisation	Surfactant nebulisation	University of Zurich	phase 3	Pulmonary surfactant replacement therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pulmonary surfactant replacement therapy class)

1. Chiesi Farmaceutici S.p.A. · 1 drug in this class
2. University of Zurich · 1 drug in this class
3. Zekai Tahir Burak Women's Health Research and Education Hospital · 1 drug in this class